Blow ups in its Celgene's (CELG) R&D pipeline have caused bulls to question the company's future growth. Generic drug makers could now pose challenges to Revlimid, the company's blockbuster cancer treatment. Celgene is currently embroiled in a tete-a-tete with Mylan (MYL) over its refusal to provide Mylan with samples to develop generic Revlimid:
Mylan, a generic drug company, wants to obtain samples to develop a generic version of Revlimid, a brand-name cancer medicine sold by Celgene. At a court hearing in Newark in December, Jonathan M. Jacobson, a lawyer for Mylan, told a federal district judge that “Revlimid costs patients who are dying $20,000 a month.”
